Geoffrey Spolyar

Partner
Full contact info

Experience

ERYTECH – $144 Million IPO

November 9, 2017

Cooley advised ERYTECH Pharma on its $143.7 million global offering of an aggregate of 6,180,137 ordinary shares, including the full exercise of the underwriters’ option to purchase additional shares. The global offering consisted of a US IPO of 5,389,021 American Depositary Shares, each representing one ordinary share and a concurrent private placement in Europe and other countries outside of the US and Canada of 791,116 ordinary shares.

Read more

Related contacts

Marc Recht
Partner, Boston
Brian Leaf
Partner, Reston
Div Gupta
Partner, New York
Courtney Thorne
Partner, Boston
Ivor Elrifi
Partner, New York
Matthew Pavao
Partner, Boston
Geoffrey Spolyar
Partner, Boston
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Aaron Pomeroy
Partner, Colorado
Stephanie Gentile
Partner, New York
Kevin King
Partner, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Francis Wheeler
Partner, Colorado
Josh Kaufman
Partner, New York

Related Practices & Industries

ZELTIQ Aesthetics to Sell to Allergan for $2.5 Billion

February 14, 2017

Cooley is advising ZELTIQ Aesthetics (NASDAQ: ZLTQ) on its approximately $2.5 billion all cash sale to Allergan (NYSE: AGN), a leading global biopharmaceutical company.

Read more

Related contacts

Barbara Borden
Partner, San Diego
Barbara Mirza
Partner, Los Angeles Santa Monica
Howard Morse
Partner, Washington, DC
Megan Browdie
Partner, Washington, DC
Matthew D. Silverman
Special Counsel, San Diego
Alla Kagan
Paralegal Specialist, San Diego
Amanda Pacheco
Associate, Palo Alto
Mark Lambert
Partner, Palo Alto
Geoffrey Spolyar
Partner, Boston
Michael Levinson
Senior Counsel, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Kevin King
Partner, Washington, DC
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Cooley Advises on Nightstar + NuCana IPOs

September 27, 2017

Cooley recently advised on the initial public offerings for UK life sciences companies Nightstar Therapeutics and NuCana. These transactions are the latest example of Cooley’s commitment and leadership in the life sciences sector.

Read more

Related contacts

Marc Recht
Partner, Boston
Brian Leaf
Partner, Reston
Div Gupta
Partner, New York
Stephen Rosen
Partner, London
Brent Siler
Senior Counsel, Washington, DC
Courtney Thorne
Partner, Boston
Tom Goodman
Partner, London
Richard Segal
Partner, New York
Paula Holland
Partner, London
Harriet Jones
Associate, London
Ivor Elrifi
Partner, New York
Heidi A. Erlacher
Partner, Boston
Geoffrey Spolyar
Partner, Boston
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Natasha Kaye
Partner, London
Stephanie Gentile
Partner, New York
Aaron Pomeroy
Partner, Colorado
Francis Wheeler
Partner, Colorado

Related Practices & Industries

Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million

July 11, 2019

Jazz Pharmaceuticals in its acquisition of Redx Pharma's (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors. Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz. Jazz will be responsible for further development, regulatory activities and commercialization. Jazz will pay Redx an upfront payment of $3.5 million. Redx is eligible to receive up to $203 million in development, regulatory and commercial milestone payments and incremental tiered royalties in mid-single digit percentage, based on any future net sales.

Related contacts

Marya Postner
Partner, Palo Alto
Geoffrey Spolyar
Partner, Boston
John Clark
Partner, London
John Wilkinson
Partner, London
Barbara Borden
Partner, San Diego
Jon Cousin
Partner, Washington, DC
Shehzad Akram
Trainee Solicitor , London
Rachel Thorn
Partner, New York

Related Practices & Industries

X4 Pharmaceuticals in its Exclusive License Agreement with Abbisko Therapeutics

September 2, 2019

Cooley advised X4 Pharmaceuticals in its exclusive license agreement with Abbisko Therapeutics granting Abbisko exclusive rights to develop and commercialize maxorixafor in combination with checkpoint inhibitors or other agents in oncology indications in China, Taiwan, Hong Kong and Macau.

Related contacts

Geoffrey Spolyar
Partner, Boston
Rachel Thorn
Partner, New York
Aaron Pomeroy
Partner, Colorado
Rick Jantz
Associate, Los Angeles Santa Monica

Related Practices & Industries

View more